Resource Summary Report

Generated by RRID on Aug 11, 2026

CD38-PE-Vio770, human

RRID:AB_2657828
Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-108-838, RRID:AB_2657828

Antibody Information

URL: http://antibodyregistry.org/AB_2657828

Proper Citation: Miltenyi Biotec Cat# 130-108-838, RRID:AB_2657828

Target Antigen: CD38

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 8-2018; Target Distribution B cells, basophils, bone marrow, brain, kidney, leukocytes, lymphocytes, monocytes, myeloid cells, NK cells, ovary, pancreatic carcinoma cells, placenta, plasma cells, red blood cells, skeletal muscle, T cells, thymocytes; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-432. (RRID:AB_2733228).

Antibody Name: CD38-PE-Vio770, human

Description: This monoclonal targets CD38

Target Organism: human

Clone ID: REA572

Antibody ID: AB_2657828

Vendor: Miltenyi Biotec

Catalog Number: 130-108-838

Record Creation Time: 20250820T043201+0000

Record Last Update: 20250820T191346+0000

Ratings and Alerts

No rating or validation information has been found for CD38-PE-Vio770, human.

Warning: Discontinued: 2021
Discontinued: 8-2018; Target Distribution B cells, basophils, bone marrow, brain, kidney, leukocytes, lymphocytes, monocytes, myeloid cells, NK cells, ovary, pancreatic carcinoma cells, placenta, plasma cells, red blood cells, skeletal muscle, T cells, thymocytes; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-432. (RRID:AB_2733228).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Werner F, et al. (2025) CD40 blockade hampers IgG class-switch while enhancing Granzyme B production by transitional B cells. Clinical and experimental immunology, 219(1).